Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Richters A, Aben KKH, Kiemeney LALM (2020) The global burden of urinary bladder cancer: an update. World J Urol 38(no 8):1895–1904. https://doi.org/10.1007/s00345-019-02984-4
2. Defossez G, Le Guyader‑Peyrou S, Uhry Z, Grosclaude P, Colonna M, Dantony E, et al (2019) Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Synthèse. Saint‑Maurice : Santé publique France, p 20
3. Grossman HB et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(no 9):859–866. https://doi.org/10.1056/NEJMoa022148
4. International Collaboration of Trialists et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol Off J Am Soc Clin Oncol 29(no 16):2171–2177. https://doi.org/10.1200/JCO.2010.32.3139
5. Pfister C et al (2021) Randomized phase III Trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER Trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79(no 2):214–221. https://doi.org/10.1016/j.eururo.2020.08.024
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献